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Abstract. Resistance to two cultured lines of murine embryonal carcinoma was 
studied in F 1 hybrids constructed between the tumor-syngeneic mouse strain 
129/J and several allogeneic strains. Three of four such hybrid strains were 
significantly more resistant to the multipotent embryonal carcinoma line PCC3 
than the tumor-syngeneic 129/J parent strain. All hybrid strains tested showed 
significantly higher resistance to the nullipotent embryonal carcinoma line F9 
than the syngeneic strain. 
Hybrid resistance to embryonal carcinoma lines does not require a hybrid 
H - 2  complex. 
Several kinds of evidence indicate that this hybrid resistance has an 
immunological basis. 
Introduction 
One of the classic laws of immunogenetics states that F 1 hybrids produced by 
crossing two inbred strains will grow tumors indigenous to either parent strain 
(Snell 1953). This law arises from the fact that histocompatibility alleles are 
expressed in a codominant manner, so a semisyngeneic F 1 hybrid will be tolerant of 
transplanted tissues originating from either of its two parental strains. However, not 
long after the formulation of these principles, Hauschka and his colleagues found 
that (C3H/St x Swiss)F 1 mice were unexpectedly resistant to both a virulent and 
attenuated line of a lymphosarcoma of C3H/St origin (Hauschka et al. 1956). This 
was followed by Shell's discovery that semisyngeneic F 1 hybrids show a reduced 
acceptance of tumor grafts compared to the susceptible parent strain (Snell 1958). 
These early observations have been repeatedly confirmed in the transplantation of a 
variety of normal and neoplastic tissues of inbred origin (Cudkowicz 1967, Kiessling 
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et al. 1975, C l a r k  et al. 1977, K l e i n  et  al. 1978, S a n f o r d  a n d  Soo  1971, S c h m i t t -  
V e r h u l s t  a n d  Z a t z  1977). i n  all  cases,  h y b r i d  r e s i s t a n c e  is a q u a n t i t a t i v e  p h e n o m -  
e n o n .  U n l i k e  t he  s t r o n g e r  a l l o g e n e i c  r e s i s t ance ,  h y b r i d  r e s i s t a n c e  c a n  be  o b s e r v e d  
o n l y  w h e n  t h r e s h o l d  c h a l l e n g e s  are  u s e d ;  l a rge  doses  of  cells  a b o l i s h  the  effect. 
A v n e r  a n d  c o - w o r k e r s  (1978) f o u n d  t h a t  (129 • C 5 7 B L / 6 ) F 1  h y b r i d s  s h o w e d  
h y b r i d  r e s i s t a n c e  to  t he  m u r i n e  e m b r y o n a l  c a r c i n o m a  cell  l ine  F9.  T h e  w o r k  we 
p r e s e n t  he r e  e x a m i n e s  F~ h y b r i d  r e s i s t a n c e  to  t he  n u l l i p o t e n t  l ine  F9  a n d  to  the  
m u l t i p o t e n t  l ine  P C C 3 .  W e  e x a m i n e  r e s i s t a n c e  to  the  t u m o r  cells in  severa l  d i f fe ren t  
s e m i s y n g e n e i c  Fa h y b r i d  hos t s ,  a n d  we d e t e r m i n e  w h e t h e r  such  r e s i s t a n c e  is 
c o n t r o l l e d  b y  f ac to r s  c lose ly  l i n k e d  to  t he  H - 2  complex .  F ina l l y ,  we i n v e s t i g a t e  
w h e t h e r  t he  r e s i s t a n c e  of  t he  ( C 5 7 B L / 6  x 129 / J )F  I h y b r i d  to  F9  is i m m u n o l o g i c a l  in  
n a t u r e .  
Materials and Methods 
Mouse strains. The inbred mouse strains 129/J-"129"-, A/J-"A"-, and SJL/J-"S"-, the congenic strain 
B10.129(6M)-"6M"-, and the F 1 hybrid strain (C57BL/6 x 129/J)Fl-"(B6 x 129)Ft"- were obtained from 
the Jackson Laboratory, Bar Harbor, Maine. F 1 hybrid mice between strain 129 and strains A, S, and 6M 
were bred in our own laboratory. At the start of an experiment, all mice were between 6 and 10 weeks old. 
The sex of the 129 parent had no detectable effect on the tumor incidence of the F~ offspring. 
Teratocarcinnma cell lines. The murine embryonal carcinoma cell lines F9-41-"F9"- and PCC3/A/1- 
"PCC3"-, syngeneic in 129/Sv mice, were employed in these experiments. Both these lines were isolated 
from transplantable teratocarcinoma OTT6050, obtained by L.C. Stevens from the grafting of a 
129/SvS1J/+ embryo to the testis of an adult mouse (Stevens 1970). The PCC3 line is developmentally 
multipotent; the F9 line is nullipotent. Karyotypically, F9 is aneuploid, whereas PCC3 is nearly diploid 
(Jacob 1977). 
Cell culture conditions. Cells were grown in Dulbecco's modified Eagle's medium containing 15% Gibco 
fetal calf serum. The cultures were maintained at 37 ~ C in a CO2/humid air mixture. Cultures were 
harvested and resnspended in fresh medium every 2-3 days. 
Histological analysis qftumors. A sample of tumors from both control and experimental animals was 
analyzed histologically for each experimental group. Tumors were fixed in Bouin's fixative, paraffin- 
processed according to Method I described in Luna (1968), and stained with hematoxylin-eosin. F9 
tumors contain only embryonal carcinoma with rare endodermal tissue areas. PCC3 tumors contain 
derivatives of all three germ layers. 
PCC3 and F9 cell injections. Cells were harvested by pipetting and resuspended in medium containing 1 
fetal calf serum. Cell viability was tested on all samples with the trypan blue dye exclusion test, and all 
doses are stated as number of viable cells injected. One-milliliter syringcs fitted with 22-gauge needles 
were used for all injections; all injections were completed within 30 rain of cell harvesting. Cells were 
injected subcutaneously, bilaterally, in volumes of 0.2 ml. 
Tumor scoring. Animals were scored for tumors regularly by palpation for a period three times as long as 
that required for tumor production in the 129 control animals. Animals scored as negative throughout 
this period were necropsied to confirm the lack of tumors. Results were pooled for male and female 
recipients, since no sex-related diffcrcnces in tmnor incidence were noted. 
Sublethal irradiation of  mice. Mice were irradiated with a a3VCs source providing a dose rate of 1000 
rad/minute. The sublethal dose used for (B6 • 129)F 1 hybrids was 650 rad. 
Lymphoid reconstitution of  mice. A lethal dose of 900 rad was given to 129 mice from the same a37Cs 
source. Lymphoid cells were taken from the bone marrow and the spleen of donor (136 x I29)Fa mice. 
Each irradiated animal received 107 bone marrow and 107 spleen ceils intravenously through the tail 
vein. Reconstituted animals were challenged 4 weeks later. 
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Immunizations. (B6 x 129)F 1 animals received bilateral subcutaneous injections of 1.2 x 104 viable F9 
cells and were challenged with a lethal dose (2 • 10 s) of F9 cells 14 days later. Animals developing tumors 
prior to the second challenge (8 of 72) were not included in the results. 
Quantitative analysis c~fresults. Dose-response data and comparisons of resistance between hybrid strains 
were analyzed according to the Wilcoxon signed rank test (Conover 1971); 2 x 2 contingency tests were 
performed upon results of experiments testing for the effects of preimmunization with live tumor cells, of 
sublethal irradiation, or of adoptive transfer of lymphoid tissues. In Tables 2, 3, and 4,/~ = the number  of 
tumor-positive 129 m i c e - t h e  number  of tumor-positive F~ mice. Absolute A values were assigned 
ranks, the lowest rank corresponding to the lowest absolute A value. In the case of ties, each member  of a 
tie was assigned a midrank value. T = the sum of all the negative ~ values. Given the null hypothesis that 
the tumor incidence of the F a hybrid will not differ significantly from that of the 129/J parent, the 
probability of T was calculated using a Wilcoxon signed-rank distribution. N = the  number  of doses 
tested. 
In Tables 5, 6, and 7, data were analyzed by a 2 x 2 contingency test according to the following 
formula: 
Given a matrix a b 
c d 
w h e r e a + b + c + d - N  
N (ad - bc) 2 
T -  
(a+b)  (c+d) x ( a + c ) ( b + d )  
The probability of T was calculated using a Chi-square distribution. 
Results 
Previous experiments have shown that (B6 x 129)F 1 hybrids are resistant to low 
doses of F9 (Avner et al. 1978). We have extended this observation to examine 
resistance to both F9 and PCC3 at a number of cell doses in four different F1 hybrid 
hosts. F~ hybrids were constructed between the syngeneic mouse strain 129 and the 
allogeneic strains B6, 6M, A, and S. These allogeneic strains are all highly resistant 
to PCC3 (Avner et al. 1978). Strains B6 and 6M are also highly resistant to F9, but A 
and S mice are susceptible to moderate (>  2 x l0 s) doses of F9 (Avner et al. 1978). 
The H-2 haplotype of each of these F~ hybrid strains is given in Table 1. Strain 6M is 
a congenic strain, possessing the H-2 region of 129 on the genetic background of 
C57BL/10 (Klein 1975). The 129 haplotype H-2 b< is a minor variant of the H-2 b 
haplotype, serologically indistinguishable from H-2 b (Klein 1975). 
Resistance oj 'F 1 hybrids to PCC3 and f'9. Results of experiments using PCC3 are 
presented in Table 2. Each hybrid strain was challenged with doses ranging from 
Table 1. H-2 haplotypes of F 1 hybrid mouse strains 
Mouse strain H-2 haplotype 
C57BL/6 x 129/.1 b/bvl 
B 10.129(6M) x 129/J bvl/bvl 
A/J x 129/J a/bvl 
SJL/J x 129/J s/bvi 
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Table 2. Tumor incidence of F 1 hybrids challenged with PCC3 
G, A. Bishop and W. F. Dove 
(a) B6 x 129 
Cell Tumor Tumor A Rank of IAI 
dose incidence-F 1 incidence-129 
4 x l0 s 10/10 10/10 0 1 
2 x l0 s 8/10 10/10 + 2  2.5 
I x l 0  s 7 / 1 0  i 0 / 1 0  + 3  4 
5 • 104 0/20 12/20 + 12 6 
2.5 x 104 12/30 16/30 +4  5 
1.25 x 104 5/20 3/20 - 2 2.5 
Sum of ranks of negative A ' s = T - 2 . 5 .  For N - 6 ,  P=0.0625. 
(b) 6M • 129 
Cell Tumor Tumor ~ Rank of I~1 
dose incidence-El incidence-129 
1 x 106 10/10 10/10 0 1 
3.3 x l0 s 5/10 10/10 + 5 4.5 
2 x l0 s 4/10 8/10 + 4  2.5 
1 x 105 4/10 10/10 + 4  2.5 
5 x 104 0/10 5/10 +5 4.5 
Sum of ranks of negative ~ ' s - T - 0 .  For N - 5 ,  P-0.031. 
(c) A • 129 
Cell Tumor Tumor A Rank of IAI 
dose incidence-F 1 incidence- 129 
3.3 x 105 10/10 10/10 0 i 
2 x l05 9/10 10/10 +1 2.5 
1 x 105 7 / 1 0  9 / 1 0  + 2  4 
5 x 10 a 4/10 8/10 +4  5 
3.3 x 10 a 0/10 1/I0 + 1 2.5 
Sum of all ranks of negative A ' s - T - 0 .  For N 5, P-0.0313. 
(d) S • 129 
Cell Tumor Tumor A Rank of IAI 
dose incidence-F 1 incidence- 129 
3.3 x l0 s 19/19 19/19 0 1 
2 x 105 10/10 9/10 1 2.5 
1 x l0 s 6/10 9/10 + 3  5 
5 • 104 7/10 9/10 + 2  4 
3.3 • 104 0/10 1/10 + 1 2.5 
Sum of ranks of negative A ' s - T  =2.5. For N - 5 ,  P-0.125.  
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o n e  t h a t  y i e lded  100~o t u m o r s  to  a n o t h e r  t h a t  y ie lded  v i r t u a l l y  0~o t u m o r s  in t he  
h y b r i d  hos t s .  All  h y b r i d s  t es ted ,  w i t h  t he  e x c e p t i o n  of  the  (S • 129)F1, s h o w e d  
s ign i f i can t ly  h i g h e r  r e s i s t a n c e  to  P C C 3  t h a n  t he  t u m o r - s y n g e n e i c  129 p a r e n t .  
Resu l t s  of  e x p e r i m e n t s  u s i n g  F9  are  p r e s e n t e d  in  T a b l e  3. H y b r i d  s t r a i n s  were  
t e s t e d  a g a i n  o v e r  a dose  r a n g e  y i e ld ing  f r o m  100~o to  0~o t u m o r s .  Al l  f ou r  of  t h e  
h y b r i d  s t r a i n s  s h o w e d  s ign i f i can t  F 1 r e s i s t a n c e  to  F9.  
Table 3. Tumor incidence of F 1 hybrids challenged with F9 
(a) B6 x 129 
Cell Tumor Tumor A Rank of IAI 
dose incidence-F1 incidence-129 
2 x l0 s 10/10 10/10 0 1.5 
1 x 105 9 /10 10/10 + 1 3 
5 • 104 2/10 10/10 + 8 8.5 
2.5 • 104 0/10 10/10 + 10 10 
1.25 x 104 2/10 10/10 + 8 8.5 
6 x 103 0/10 6/10 +6 6 
3 x l03 2/10 9/10 +7 7 
1.5 x 103 0/10 2/10 +2 4 
7.5 • 10 z 0/10 3/10 +3 5 
3.75 x 102 0/10 0/10 0 1.5 
Sum of ranks of negative A ' s - T - 0 .  For N -  10,P -0.001. 
(b) 6M x 129 
Cell Tumor Tumor A Rank of IAI 
dose incidence-F1 incidence-129 
5 • l05 10/10 10/10 0 1 
2 • 105 7/10 10/10 +3 2 
1 • 105 4/10 10/10 +6 3 
5 x 104 2/10 10/10 +8 5 
2.5 • 104 2/17 13/17 +11 6 
1.25 x 104 0/10 7/10 +7 4 
Sum of ranks of negative A's - T = 0. For N = 6, P -- 0.0156. 
(c) A • 129 
Cell Tumor Tumor /~ Rank of ]A] 
dose incidence-F1 incidence-129 
2 x 105 10/10 10/10 0 1 
1 x 105 7/10 10/10 + 3  4 
5 • 104 16/20 17/20 + 1 2 
2.5 • 104 5/10 8/10 +3 4 
1.25 • 104 12/20 16/20 +4  6 
6 x 103 0/10 3/10 +3 4 
Sum of ranks of negative A ' s - T = 0 .  For N~6,  P-0.0156. 
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(d) S • t 29 
Cell Tumor  Tumor  A Rank of IAI 
dose incidence-F 1 incidence-129 
2 • lO 5 lO/lO lO/lO 0 1.5 
1 x 105 9 / 1 0  1 0 / 1 0  + 1 4 
5 • 104 7/10 10/10 +3  7 
2.5 • 104 6/10 7/10 + 1 4 
1.25 x 104 6/10 10/10 + 4  8 
6 x 103 8/10 9/10 + 1 4 
3 x 103 3/10 5/10 + 2 6 
1.5 x 103 4/10 4/10 0 1.5 
Sum of ranks of negative A ' s  T =0.  For N - 8 ,  P-0.0039.  
W h e n  t h e  m a g n i t u d e  o f  h y b r i d  r e s i s t a n c e  t o  F 9  w a s  e x a m i n e d ,  it w a s  d i s c o v e r e d  
t h a t  t h e  s t r a i n s  fa l l  i n t o  t w o  g r o u p s .  S t r a i n s  (B6  x 129 )F  t a n d  ( 6 M  x 1 2 9 ) F  1 b e l o n g  
t o  a h i g h  r e s i s t a n c e  c a t e g o r y ,  w h e r e a s  s t r a i n s  (A x 1 2 9 ) F  1 a n d  (S x 1 2 9 ) F l  b e l o n g  to  
Table 4. Comparison of strength of hybrid resistance to F9 between F 1 strains 
(a) (B6• 129)F 1 vs. (6M • 129)F 1 
Cell ~ Tumor-negative ~ Tumor-negative A Rank of IAI 
dose Ft  mice - 129 controls 
(B6 x 129)F 1 (6M x 129)F 1 
2 • 105 0 0 0 1.5 
1 x 105 10 60 50 5 
5 x 104 80 80 0 1.5 
2.5 x 10" 100 64 +36  4 
1.25 • 104 80 70 + 10 3 
Sum of ranks of negative ~ ' s = T  5. 
For N = 5 ,  P=0.3125. 
(b) (A • 129)F 1 vs. (S • 129)F1 
Cell ~ Tumor-negative ~ Tumor-negative A Rank of IA] 
dose F 1 mice - 129 controls 
(A • 129)F, (S x 129)F1 
2 • 105 0 0 0 1 
1 • 105 30 10 + 2 0  3 
5 x l04 5 30 25 5 
2.5 x 104 30 10 +20  3 
1.25 x 104 20 40 20 3 
Sum of ranks of negative A ' s  = T - - 8 .  
For N =5,  P~0.59.  
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(c) "C57"F 1 vs. "A, S" F x 
Cell % Tumor-negative "~o Tumor-negative A Rank of IAI 
dose F~ mice - 129 controls 
"C57" F 1 "A,S" F1 
2 • 0 0 0 1 
1 x 105 35 20 + 15 2 
5 • 80 13 +65 5 
2.5 x 10  4 78 20 +58 4 
1.2 • 10  4 75 27 +48 3 
Sum of ranks of negative A's = T =0. For N = 5, p =0.031. 
a low resistance group (Table 4, parts a and b). Data  from each group were pooled 
and compared  (Table 4, part  c). It was found that hybrid resistance to F9 was 
significantly stronger in the "C57" group than in the '%, S" group (P = 0.03). This 
may indicate the presence of a strong factor for hybrid resistance in the C57BL 
background  (common to the B6 and 6M strains) that  is absent in the A and S strain 
backgrounds.  
Evidence that hybrid resistance to F9 is an immunological response. The (B6 x 129)F 1 
hybrid strain, which demonstrated strong F 1 resistance to F9 and significant 
resistance to PCC3, was chosen for further studies. The first of these involved an 
attempt to increase the hybrid resistance by preimmunizing with sublethal doses of 
viable F9 cells. The immunizat ion procedure is described in Materials and Methods. 
The results, presented in Table 5, show that preimmunized FI were significantly 
more resistant to challenge with lethal doses of F9 than their nonimmunized 
counterparts  (X2=4.5;  P=0.02) .  A more conservative estimate of the level of  
significance would classify the eight animals that incurred tumors  from the 
preimmunizat ion dose as tumor-posit ive in the set of challenged animals. This 
estimate gives X 2 =  2.56, P =0.04. 
Tota l -body  irradiation with sublethal levels of X-rays eliminates many  immu- 
nological responses. Avner and co-workers (1978) found that sublethal to ta l -body 
irradiation diminished the resistance to F9 of (B6 x 129)F~ hybrids; Our  results 
(Table 6) confirm this observation. Sublethally irradiated (B6 x 129)F 1 mice were 
unable to resist a sublethal dose of F9 cells to which unirradiated control  hybrids 
showed a high degree of resistance (X 2 =25.1;  P<0.001).  
Adoptive transfer of immunocompeten t  cells provides a positive test for the 
immunological  basis of a response. Thus, the capacity of the (B6 x 129)F 1 hybrid to 
transfer its resistance to the tumor-permissive 129 parent strain was tested. 
Construct ion of 129e-F1 radiat ion chimeras is described in Materials and Methods; 
results are presented in Table 7, The chimeras showed a highly significant increase in 
resistance to F9 (part a; X 2 = 11.75 ; p < 0.001 ); this resistance approached  that of the 
F 1 hybrid itself (part b; X 2 =  1.2; p>0.16) .  
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Table 5. Immunization of (B6 x 129)F 1 mice 
G. A. Bishop and W. F. Dove 
Total Tumor-negative Tumor-positive 
Control hybrids 72 19 (26~o) 53 (74~) 
Immunized hybrids 64 28 (44~,) 36 (56~o) 
Hybrids were immunized with sublethal doses of F9, as described in Materials and Methods. These 
animals and their age- and sex-matched controls were challenged at the same time with 2 x 105 F9 cells 
from the same preparation. 
Discussion 
The present experiments extend previous observations on F1 hybrid resistance to 
murine embryonal  carc inoma cells (Avner et al. 1978). We have studied resistance to 
both mult ipotent  and nullipotent cell lines of a murine tera tocarc inoma in four 
strains of F 1 mice semisyngeneic to the strain of tumor  origin. 
Most  of the F1 hybrid strains showed significant resistance to both embryonal  
carc inoma cell lines PCC3 and F9. Our  results concerning the H-2 control  of this 
hybrid resistance fit the pat tern described by Klein and co-workers (1978), who 
reported that  F~ hybrid resistance to three carcinomas and two sarcomas failed to 
show significant linkage to the H-2 complex. In the present studies, the hybrid 
(6M x 129)F1 showed undiminished resistance to both embryonal  carc inoma cell 
lines tested, a l though the H-2 haplotype of this hybrid is homozygous  and identical 
to that of the inbred syngeneic 129 parent. Resistance of the (6M • 129)Fa hybrid 
was equal in strength to that  of the H-2 heterozygote (B6 • 129)F 1. Thus, we 
conclude that  heterozygosity of the H-2 region is not necessary to account  for 
hybrid resistance to the embryonal  carc inoma cell lines PCC3 and F9. 
Avner and co-workers (1978) showed that B6 carries strong allograft rejection 
character(s) for F9, whereas A and S do not. It is possible that the same character(s) 
responsible for this difference in allograft rejection continues to operate in the 
semisyngeneic hybrid host. This could account  for the greater hybrid resistance of 
the "C57BL" group (Table 4). In principle, such a character could be either a 
dominant  immune-response factor in the B6 genome or else a strong histocompati-  
bility difference for which the 129 allele is incompletely expressed in the F1 hybrid. 
The basis of resistance in the (B6 x 129)F 1 mouse to F9 appears to be an immune 
response to an antigenic determinant  (or determinants) present on the embryonal  
carc inoma cell. This conclusion stems from the observations that: (a) F 1 hybrid 
Table 6. Sensitivity of sublethally irradiated (B6 x 129)F~ mice to F9 
Tumor-negative m i c e  Tumor-positive mice 
Irradiated hybrids 1 20 
Nonirradiatcd hybrids 19 5 
Mice were irradiated as described in Materials and Methods. Irradiated mice and their age- and sex- 
matchcd controls received a sublethal challenging of F9 cells (2.5 x 104) subcutaneously bilaterally using 
the same cell suspension. 
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Table 7. Resistance of 12%-F t chimeras to F9 
Tumor-negative mice Tumor-positive mice 
129 4 25 
F1 22 9 
Chimeras 16 12 
Construction of 129+--F 1 chimeras is described in Materials and Methods. Chimeras, 129 controls, and F 1 
controls were age-matched and were challenged at the same time from the same cell suspension. All 
animals received 2.5 x 104 F9 cells subcutaneously bilaterally, a dose that is lethal for the 129 strain but 
sublethal for the F1 strain. 
resistance is eliminated by sublethal doses of total-body irradiation, (b) hybrid 
resistance is adoptively transferred via lymphoid cells from a naive F 1 mouse, and (c) 
the resistance of the hybrids is heightened by preimmunization using live tumor 
cells. The positive effect of preimmunization, although not large, gives important 
evidence that hybrid resistance is immunological. 
Does preimmunization heighten the same immune-response channel as that 
operating in hybrid resistance? Or, does it act in animals protected by hybrid 
resistance to heighten other channels ? We have not tested whether syngeneic hosts 
can be preimmunized by live tumor cells; the doses sublethal for F1 hosts would be 
lethal in syngeneic hosts. We note with interest the report of Boon and Van Pel 
(1978) that syngeneic hosts can be preimmunized by live attenuated (turn-) 
embryonal carcinoma variants. It is possible that F 1 resistance operates on the same 
channel as that elicited in the syngeneic host by Boon and Van Pel's procedure. 
Our experiments do not permit identification of the embryonal carcinoma 
antigen(s) to which the F 1 hybrid responds. It is unlikely to be encoded at the H-2 
locus because the (6M x 129)F1 is fully syngeneic at this locus but shows unabated 
hybrid resistance. 
Hybrid resistance is also unlikely to be directed against the male-specific antigen 
H(Y). PCC3 lacks the Y chromosome (Nicolas et al. 1976), and we have observed no 
difference in the level of resistance between male and female hybrids (data not 
shown). 
A third unlikely candidate for the transplantation antigen against which hybrid 
resistance is directed is the F9 antigen (Artzt et al. 1974, Kemler et al. 1976, 
Marticorena et al. 1978). This embryonic antigen is immunogenic in the syngeneic 
host, as judged by serological response; for it to form the basis of graft rejection in 
hybrids and not in the syngeneic host would thus require an additional hypothesis. 
One interesting candidate for the transplantation antigen for hybrid resistance is 
the antigen associated with the Gross leukemia virus, G~x. This antigen is found on 
adult lymphoid cells and in some malignant tissues; 129 is a positive strain, whereas 
B6 is negative (Klein 1975). Obata and his co-workers (1976) have studied the 
genetic control of the serological response to G~x. Although the syngeneic strain 129 
is antigen-positive and seronegative, and the antigen-positive congenic strain 
B6.129 is also seronegative, the F1 hybrids (129 x B6) and (129 x B6.129) are 
seropositive. These workers have suggested that B6 and 129 carry dominant 
immune-response factors that cooperate to permit a serological response to the Glx 
auto-antigen encoded by the 129 genome. 
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Though embryonal carcinoma cells in culture show no evidence for virus growth 
(Jacob 1977), it is not known whether F9 or PCC3 carry the Gix antigen. Its 
involvement in hybrid resistance is, therefore, only conjectural at this time. 
The studies reported here demonstrate that resistance of (129 • B6) hybrids to 
F9 teratocarcinoma transplants is mediated by lymphoid tissue and does not 
depend upon heterozygosity at the H-2 locus. The multipotent line PCC3 is also 
susceptible to hybrid resistance. Semisyngeneic hybrids involving A/J or SJL/J as 
the allogeneic parent also display hybrid resistance to F9 and PCC3. The target 
antigen(s) and the immune mechanisms(s) of transplant rejection remain to be 
determined. 
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